Two million Canadians suffer from this chronic inflammatory skin
disease; March is Rosacea Awareness Month
THORNHILL, ON, Feb. 27, 2013 /CNW/ - Galderma Canada Inc. today
announced Apprilon™, an innovative, anti-inflammatory rosacea
treatment, is now available for prescription in Canada. Apprilon
(Doxycycline Modified-Release Capsule, 40 mg) is the first and only
oral, once-daily therapy designed specifically to treat the bumps and
pimples associated with rosacea, and does not cause complications
associated with long-term antibiotic use.1,2,3
Rosacea affects more than two million Canadians, most commonly
individuals with fair skin and between the ages of 30 and 60.4 Symptoms typically include small red bumps that sometimes contain pus,
red or pink patches, and visible tiny broken blood vessels. The most
common sites for flare ups include the nose, chin and forehead. Because
symptoms can be similar to those of acne, it is often misdiagnosed as
"Rosacea can be a painful and even embarrassing condition for sufferers
to deal with. For the first time, Apprilon offers a convenient,
once-daily oral treatment option that will make it easier for patients
to follow their treatment regimen and ultimately get better results,"
says Dr. Benjamin Barankin, medical director at the Toronto Dermatology
Centre. "Apprilon is a unique treatment because of its
anti-inflammatory properties. It effectively treats the inflammatory
lesions caused by rosacea without displaying antibiotic activity, which
will allow me to treat patients for long periods of time without the
complications or side effects associated with traditional antibiotic
Recent evidence suggests rosacea is primarily an inflammatory condition,
not a bacterial infection. Apprilon is the only medication that reduces
the inflammatory response in patients with rosacea without producing
drug concentrations required to treat bacterial diseases.1 Each Apprilon capsule contains two types of beads that together provide
a dose of 40 mg of doxycycline, an antibiotic in the tetracycline
family. The immediate-release beads contain 30 mg of doxycycline and
the delayed-release beads contain 10 mg of doxycycline.1 Clinical studies show the combination of immediate and delayed-release
beads keeps Apprilon at a very low dose that will not produce
antibiotic resistance over the long term.
Marketed as Oracea™ in the United States, the availability of Apprilon
in Canada reinforces Galderma's commitment to providing novel skin care
In two clinical trials, Apprilon demonstrated a significant reduction in
total inflammatory lesions (i.e. papules, pustules, nodules) at 16
weeks, compared to placebo.1,2 Apprilon was also associated with a rapid onset of action, achieving a
significantly greater decrease in total inflammatory lesion count than
placebo by the first follow-up visit at week three in both studies.1,2
Apprilon is now available for prescription across Canada. Patients
should speak with their family doctor or dermatologist to learn more
about Apprilon and its suitability for their skincare needs.
About Galderma Canada Inc.
Galderma Canada Inc. is a pharmaceutical company specializing in
research and marketing of therapeutic, corrective and aesthetic
solutions for dermatology patients. Our expertise spans a broad
spectrum of skin and hair diseases. Our growing portfolio includes
treatments for skin conditions such as acne, rosacea, psoriasis,
eczema, skin cancers, and seborrheic dermatitis.
Galderma Canada Inc. was established in 1989 as an affiliate of
Galderma, a global pharmaceutical company. Today, with a staff of 42,
half of which is located in Thornhill, Ontario, we service more than
3,500 physicians in Canada with a special focus on dermatology.
Apprilon™ Product Monograph, Galderma Canada Inc., August 30, 2012
Del Rosso JQ, Webster G, Jackson M, Rendon M, Rich P, Torok H, MD,
Bradshaw M. Two randomized phase III clinical trials evaluating
anti-inflammatory dose doxycycline (40-mg doxycycline, USP capsules)
administered once daily for treatment of rosacea. J Am Acad Dermatol.
American Acne & Rosacea Society. Rosacea Medical Management Guidelines.
Canadian Skin Patient Alliance. Overview: What is rosacea? www.skinpatientalliance.ca Last accessed January 24, 2013.
Canadian Dermatology Association. Patient Education Brochure: Rosacea.
SOURCE: Galderma Canada Inc.
For further information:
For additional information or interviews, please contact:
416-968-7311 ext 243